US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Faeth Therapeutics

24.54

+0.54002.25%

Post-market: 24.540.00000.00%16:10 EDT

Volume:102.82K

Turnover:2.66M

Market Cap:632.61M

PE:-0.17

High:27.77

Open:24.05

Low:24.05

Close:24.00

52wk High:36.76

52wk Low:6.33

Shares:25.78M

Float Shares:811.70K

Volume Ratio:0.81

T/O Rate:12.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-142.7282

EPS(LYR):-16.7239

ROE:--

ROA:-95.24%

PB:-4.61

PE(LYR):-1.47

Loading ...

Overview Company News Filings

Faeth Therapeutics CFO Brian C. Stephenson files initial beneficial ownership statement

Faeth Therapeutics Initiated at Buy by HC Wainwright & Co.

HC Wainwright Initiates Faeth Therapeutics at Buy With $60 Price Target

MT Newswires Live

Faeth Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Faeth Therapeutics Launches New At-the-Market Equity Program

Sensei Biotherapeutics enters at-the-market equity distribution agreement for up to $150 million stock sale

Faeth Therapeutics files automatic mixed securities shelf

Faeth Therapeutics Enters Into Sales Agreement for Offering of up to $150 Mln

THOMSON REUTERS

Faeth Therapeutics, Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS

Sensei Biotherapeutics director Stephen M. Hahn files initial beneficial ownership statement

Sensei Biotherapeutics Price Target Maintained With a $55.00/Share by BTIG

Sensei Biotherapeutics changes name to Faeth Therapeutics, adopts ticker FTH

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing Piktor, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

THOMSON REUTERS

Sensei Biotherapeutics - Appoints Anand Parikh as Chairman, President and CEO Effective June 12, 2026

THOMSON REUTERS

Sensei Biotherapeutics - Piktor Phase 1B/2 Interim Data in Hr+/Her2- Advanced Breast Cancer Expected in 2027

THOMSON REUTERS

Sensei Biotherapeutics - Appoints Brian Stephenson as Chief Financial Officer

THOMSON REUTERS

Sensei Biotherapeutics - Common Stock to Begin Trading as Fth on Nasdaq on June 16, 2026

THOMSON REUTERS

Sensei Biotherapeutics - Piktor Phase 2 Topline Data in Advanced Endometrial Cancer Expected Second Half 2026

THOMSON REUTERS

Press Release: Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/FTH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FTH\",,,,,undefined,":{"symbol":"FTH","market":"US","secType":"STK","nameCN":"Faeth Therapeutics","latestPrice":24.54,"timestamp":1782331200000,"preClose":24,"halted":0,"volume":102819,"hourTrading":{"tag":"盘后","latestPrice":24.54,"preClose":24.54,"latestTime":"16:10 EDT","volume":386,"amount":9472.44,"timestamp":1782331805188,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.022499999999999964,"floatShares":811700,"shares":25778800,"eps":-142.7282,"marketStatus":"Post-Mkt","change":0.54,"latestTime":"06-24 16:52:37 EDT","open":24.05,"high":27.77,"low":24.05,"amount":2655382,"amplitude":0.155,"askPrice":28.8,"askSize":70,"bidPrice":24,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-142.7282,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1782345600000},"marketStatusCode":4,"adr":0,"listingDate":1612414800000,"exchange":"NASDAQ","adjPreClose":24,"preHourTrading":{"tag":"盘前","latestPrice":23.11,"preClose":24,"latestTime":"09:22 EDT","volume":56,"amount":1337.459928,"timestamp":1782307368421,"change":-0.89,"changeRate":-0.037083,"amplitude":0.037083},"postHourTrading":{"tag":"盘后","latestPrice":24.54,"preClose":24.54,"latestTime":"16:10 EDT","volume":386,"amount":9472.44,"timestamp":1782331805188,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.814321},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FTH\",,,,,undefined,":{"symbol":"FTH","floatShares":811700,"roa":"-95.24%","roe":"--","lyrEps":-16.72388,"volumeRatio":0.814321,"shares":25778800,"dividePrice":0,"high":27.77,"amplitude":0.155,"preClose":24,"low":24.05,"week52Low":6.325,"pbRate":"-4.61","week52High":36.76,"institutionHeld":0,"latestPrice":24.54,"committee":-0.75,"eps":-142.7282,"divideRate":0,"volume":102819,"delay":0,"ttmEps":-142.7282,"open":24.05,"prevYearClose":10.67,"prevWeekClose":17.82,"prevMonthClose":21.14,"prevQuarterClose":31.52,"fiveDayClose":14.53,"twentyDayClose":16.47,"sixtyDayClose":27.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FTH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-15","symbol":"FTH","fiscalQuarterEnding":"2026/03","expectedEps":-0.62,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-131.45},{"market":"US","date":"2026-03-30","symbol":"FTH","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-3.74},{"market":"US","date":"2025-11-14","symbol":"FTH","fiscalQuarterEnding":"2025/09","expectedEps":-4.11,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-3.62},{"market":"US","date":"2025-08-05","symbol":"FTH","fiscalQuarterEnding":"2025/06","expectedEps":-6.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"pre","actualEps":-3.91},{"market":"US","date":"2025-06-17","symbol":"FTH","defaultRemindTime":1750167000000,"type":"split","dateTimestamp":1750132800000,"forFactor":20,"toFactor":1,"ratio":20}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FTH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FTH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1782187200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FTH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FTH","date":"2026-06-23","current":-0.18784,"percent":0,"low":-0.168709,"twenty":-0.145269,"median":-0.125386,"eighty":-0.114961,"high":-0.105707,"avg":-0.131297,"sd":0.023241,"marketCap":31119611},"quantilePoints":[{"date":"2026-06-18","current":-0.12113,"twenty":-0.118045,"median":-0.113419,"eighty":-0.108792,"marketCap":22343317},{"date":"2026-06-23","current":-0.168709,"twenty":-0.145269,"median":-0.125386,"eighty":-0.114961,"marketCap":31119611}],"updateTime":1782324193656},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FTH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645465854","title":"Faeth Therapeutics CFO Brian C. Stephenson files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2645465854","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645465854?lang=en_us&edition=fundamental","pubTime":"2026-06-24 05:22","pubTimestamp":1782249758,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics CFO Brian C. Stephenson filed an initial ownership report showing a stock option for 166,435 shares at $29.37, expiring March 10, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL9TNMfC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029082","title":"Faeth Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029082","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029082?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:14","pubTimestamp":1782126840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FTH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 07:14 ET (11:14 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025142","title":"HC Wainwright Initiates Faeth Therapeutics at Buy With $60 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025142","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645025142?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:10","pubTimestamp":1782123010,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Faeth Therapeutics at Buy With $60 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645255680","title":"Faeth Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2645255680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645255680?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:01","pubTimestamp":1782122477,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nAZN4T3J2B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042865","title":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645042865?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:47","pubTimestamp":1782114448,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, VisteonJune 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYD","CHRD","FANG","FMC","LINT","AGMB","MULL","GLW","KLAG","AALG","ALT","ALGM","DAR","INTC","MUU","AAL","BILL","KMX","BWIN","VC","KR","AMAT","FPS","ABVX","MRK","MRNX","MTDR","INTW","CNXU","DFTX","LGN","HCA","INCY","KLAC","LRCU","NBIX","AMRZ","LQDA","MU","DCH","APGE","MRNA","FTH","ARMK","LRCX","ENPH","BWXT","DAL","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644032311","title":"Faeth Therapeutics Launches New At-the-Market Equity Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2644032311","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644032311?lang=en_us&edition=fundamental","pubTime":"2026-06-19 07:26","pubTimestamp":1781825192,"startTime":"0","endTime":"0","summary":"The latest update is out from Faeth Therapeutics ( ($FTH) ). On June 18, 2026, Faeth Therapeutics, Inc. entered into a sales agreement with TD Secu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/faeth-therapeutics-launches-new-at-the-market-equity-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/faeth-therapeutics-launches-new-at-the-market-equity-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","BK4588","BK4585","EQR","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644318320","title":"Sensei Biotherapeutics enters at-the-market equity distribution agreement for up to $150 million stock sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2644318320","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644318320?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:13","pubTimestamp":1781817225,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics entered an at-the-market equity distribution agreement with TD Securities  to sell up to USD 150 million of common stock.Agent to sell shares from time to time under company instructions; commission up to 3% of gross sales.Series B non-voting convertible preferred stock converted into 24,435,594 common shares; common shares outstanding rose to 25,778,754 as of June 15, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensei Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL51vhLG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNSE","BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644036247","title":"Faeth Therapeutics files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2644036247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644036247?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:05","pubTimestamp":1781813140,"startTime":"0","endTime":"0","summary":"16:03 EDT Faeth Therapeutics (FTH) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/faeth-therapeutics-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/faeth-therapeutics-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644673036","title":"Faeth Therapeutics Enters Into Sales Agreement for Offering of up to $150 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2644673036","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644673036?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:03","pubTimestamp":1781812980,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0J7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644036571","title":"Faeth Therapeutics, Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644036571","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644036571?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:03","pubTimestamp":1781812980,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0J7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644603587","title":"Sensei Biotherapeutics director Stephen M. Hahn files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2644603587","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644603587?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:19","pubTimestamp":1781641173,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics director Stephen M. Hahn reported holding 44,763 shares underlying Series B Preferred Stock in an initial Form 3 filing dated June 12, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensei Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLfkvCs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNSE","BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643279207","title":"Sensei Biotherapeutics Price Target Maintained With a $55.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2643279207","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643279207?lang=en_us&edition=fundamental","pubTime":"2026-06-16 01:12","pubTimestamp":1781543520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNSE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 15, 2026 13:12 ET (17:12 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203988","title":"Sensei Biotherapeutics changes name to Faeth Therapeutics, adopts ticker FTH","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203988","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203988?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525416,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics rebranded as Faeth Therapeutics, pivoting to PIKTOR, an oral multi-node inhibitor of the PI3K/AKT/mTOR pathway.Common stock expected to trade on Nasdaq under ticker FTH on June 16, 2026.Company cited $200 million in gross proceeds from a private placement tied to its February 2026 Faeth acquisition.PIKTOR Phase 2 topline data in advanced endometrial cancer targeted for the second half of 2026; breast cancer interim data expected in 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDLb5lBPr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","BK4139","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643920350","title":"Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing Piktor, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643920350","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643920350?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FTH","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643605203","title":"Sensei Biotherapeutics - Appoints Anand Parikh as Chairman, President and CEO Effective June 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643605203","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643605203?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNSE","FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203953","title":"Sensei Biotherapeutics - Piktor Phase 1B/2 Interim Data in Hr+/Her2- Advanced Breast Cancer Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203953","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203953?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNSE","BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203677","title":"Sensei Biotherapeutics - Appoints Brian Stephenson as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203677","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203677?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH","BK4139","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203603","title":"Sensei Biotherapeutics - Common Stock to Begin Trading as Fth on Nasdaq on June 16, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203603?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FTH","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643039582","title":"Sensei Biotherapeutics - Piktor Phase 2 Topline Data in Advanced Endometrial Cancer Expected Second Half 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643039582","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643039582?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH","SNSE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203959","title":"Press Release: Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203959","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203959?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":"-- Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement --. -- Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol \"FTH\" on June 16, 2026 --. -- Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry --. -- PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, on track for topline Phase 2 data in advanced endometrial cancer in the second half of 2026 --. Effective June 12, 2026, the Company appointed a new executive leadership team. Anand Parikh, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH","SNSE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}